亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業(yè)會員第1年

武漢昌達順科技有限公司  

醫(yī)藥原料及中間體,生物制品,營養(yǎng)補充劑等

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:王女士
  • 電話:027-87290258
  • 郵件:changdashun1010@163.com
  • QQ:497617324
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 格列美脲
格列美脲
單價 面議對比
詢價 暫無
發(fā)貨 湖北武漢市付款后3天內
過期 長期有效
更新 2014-03-12 17:38
 
詳細信息
 格列美脲
英文名稱:Glimepiride
化學名稱:1-(4-[2-(3-乙基-4-甲基-2-氧代-3-吡咯啉-1-甲酰胺基) -乙基 [苯磺酰)-3-(反式-4-甲基環(huán)己基)] 尿
CAS NO: 93479-97-1
含量:98.0-102.0%
分子式:C24H34N4O5S
分子量:490.62
包裝:5KG鋁聽、25kg紙板桶
外觀:白色結晶粉末
熔點:205~209°C
干燥失重:≤1.0%
含量:≥99%
重金屬:≤20PPM
質量標準:USP29
用途:格列美脲為第三代磺酰脲類長效抗糖尿病藥,其作用機制是通過與胰腺β-細胞表面的磺酰脲受體 (相對分子質量為6.5×104的蛋白質)結合,此受體與ATP敏感的K+(KATP)通道相耦連,促使KATP通道關閉,引起細胞膜的去極化,使電壓依賴性鈣通道開放, Ga2+內流而促使胰島素的釋放,并抑制肝葡萄糖的合成。
 
 
©2025 武漢昌達順科技有限公司 版權所有   技術支持:化工網   訪問量:5778  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |